KURZPROTOKOLL
Her2CLIMB

Öffentlicher Titel	Phase II Studie zu Tucatinib bei fortgeschrittenem HER2-positivem Brustkrebs
Wissenschaftl. Titel	Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Kurztitel	Her2CLIMB
Studienart	multizentrisch, prospektiv, Therapiestudie, randomisiert, Pharma-Studie, doppelblind, zweiarmig
Studienphase	Phase II
Erkrankung	Geschlechtsorgane: Brustkrebs: Erstlinie Geschlechtsorgane: Brustkrebs: Zweitlinie oder höher
Einschlusskriterien	- Have histologically confirmed HER2+ breast carcinoma, with HER2+ defined by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) methodology - Have received previous treatment with trastuzumab, pertuzumab, and T-DM1 - Have progression of unresectable locally advanced or metastatic breast cancer after last systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy - Have measurable or non-measureable disease assessable by RECIST 1.1 - Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 - At least 18 years of age at time of consent - Have adequate hepatic function - Have adequate baseline hematologic parameters - Have creatinine clearance >= 50 mL/min or, in patients <= 45 kg in weight, a serum creatinine within institutional normal limits - Have left ventricular ejection fraction (LVEF) >= 50% - If female of childbearing potential, must have a negative result of serum pregnancy test. - Women of childbearing potential and men with partners of childbearing potential must agree to use a highly effective birth control methods. - CNS Inclusion – Based on screening contrast brain magnetic resonance imaging (MRI), patients must have one of the following: a) No evidence of brain metastases; b) Untreated brain metastases not needing immediate local therapy; c) Previously treated brain metastases: c1) Brain metastases previously treated with local therapy my either be stable since treatment or may have progressed since prior local CNS therapy; c2) Patients treated with CNS local therapy for newly identified lesions found on contrast brain MRI performed during screening for this study may be eligible to enrol if all of the following criteria are met: i.) Time since whole brain radiation therapy (WBRT) is >= 21 days prior to first dose of treatment, time since stereotactic radiosurgery (SRS) is >= 7 days prior to first dose of treatment, or time since surgical resection is >= 28 days; ii.) Other sites of evaluable disease are present; c3) Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions
Ausschlusskriterien	- Have previously been treated with: a) lapatinib within 12 months of starting study treatment (except in cases where lapatinib was given for <= 21 days and was discontinued for reasons other than disease progression or severe toxicity); b) neratinib, afatinib, or other investigational HER2/epidermal growth factor receptor (EGFR) or HER2 tyrosine kinase inhibitor (TKI) at any time previously.

	- Have previously been treated with capecitabine for metastatic disease(except in cases where capecitabine was given for <= 21 days and was discontinued for reasons other than disease progression or severe toxicity) . Note patients who have received capecitabine for adjuvant or neoadjuvant treatment at least 12 months prior to starting study treatment are eligible. - Have any toxicity related to prior cancer therapies that has not resolved to <= Grade 1 - Have clinically significant cardiopulmonary disease - Are known carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease - Are known to be positive for human immunodeficiency virus (HIV) - Require therapy with warfarin or other coumarin derivatives - Unable for any reason to undergo contrast MRI of the brain - CNS Exclusion – Based on screening brain MRI, patients must not have any of the following: a) Any untreated brain lesions > 2.0 cm in size unless discussed with medical monitor and approval for enrolment is given; b) Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total dose of > 2mg dexamethasone; c) Any brain lesion thought to require immediate local therapy. Patients who undergo local treatment for such lesions identified by screening MRI may still be eligible for the study based on criteria described under CNS inclusion criteria 19b; d) Known or concurrent leptomeningeal disease (LMD)
Alter	18 Jahre und älter
Molekularer Marker	HER2/neu pos.
Prüfzentren	**Sana Klinikum Offenbach** (Rekrutierung beendet) Starkenburgring 66 63069 Offenbach Benjamin Schnappauf Tel: 069 8405-7032 Fax: 069 8405-4486 benjamin.schnappauf@sana.de
Sponsor	Cascadian Therapeutics
Förderer	Cascadian Therapeutics
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT02614794 EudraCT 2015-002801-12